MARKET

ALLK

ALLK

Allakos
NASDAQ

Real-time Quotes | Nasdaq Last Sale

68.38
+1.30
+1.94%
After Hours: 68.38 0 0.00% 16:41 07/10 EDT
OPEN
66.57
PREV CLOSE
67.08
HIGH
69.08
LOW
66.17
VOLUME
149.68K
TURNOVER
--
52 WEEK HIGH
139.99
52 WEEK LOW
30.32
MARKET CAP
3.33B
P/E (TTM)
-34.3808
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALLK stock price target is 82.00 with a high estimate of 131.00 and a low estimate of 34.00.

EPS

ALLK News

More
Hedge Funds Dropped The Ball On Allakos Inc. (ALLK)
Insider Monkey · 07/05 20:31
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
GlobeNewswire · 06/03 13:01
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --   -- Top-line safety and efficacy results from both studies expected in the second half
Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --   -- Top-line safety and efficacy results from both studies expected in the second half · 06/03 12:15
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 05/27 08:20
61 Stocks Moving In Tuesday's Mid-Day Session
Gainers Mmtec, Inc. (NASDAQ: MTC) shares jumped 98.2% to $2.18 in pre-market trading after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 05/26 16:29
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020
GlobeNewswire · 05/21 13:01
Why Allakos (ALLK) Stock Might be a Great Pick
Zacks · 05/15 14:02
All You Need to Know About Allakos Inc (ALLK) Rating Upgrade to Buy
Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Zacks · 05/14 16:00

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ALLK

Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
More

Webull offers kinds of Allakos Inc stock information, including NASDAQ:ALLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALLK stock methods without spending real money on the virtual paper trading platform.